Respiratory support of adults in the emergency department: A protocol for a prospective, observational, multicenter point prevalence study
- PMID: 36467757
- PMCID: PMC9713315
- DOI: 10.1002/hsr2.966
Respiratory support of adults in the emergency department: A protocol for a prospective, observational, multicenter point prevalence study
Abstract
Background and aims: Providing respiratory support (RS) to patients may improve their oxygenation and ventilation, reducing the work of breathing. Emergency department (ED) patients often need RS; COVID-19 has heightened this need. Patients receiving RS may need escalation of their treatment; hence, studies considering the prevalence of escalation are warranted.
Method: This is a protocol for a prospective, observational, multicenter point prevalence study (PPS). Researchers will collect data over 2 days. All participants are adult ED patients needing RS. The setting is four EDs in New Zealand. The primary research question asks, "Which patients receiving RS require escalation of therapy in the ED?" For example, transitioning from conventional oxygen therapy (COT) to intubation is deemed an escalation of therapy. A sample size of 80 participants is required to resolve the primary research question. Secondary research questions: (1) Which patients receive nasal high flow (NHF) in the ED? (2) How is NHF therapy delivered in the ED? (3) What are the effects of NHF therapy on physiological and patient-centered outcomes? Research Electronic Data Capture (REDCap) will be used for data organization. Data will be imported for analysis from REDCap to IBM SPSS software (Statistics for Windows, Version 27.0). Data reporting on the primary outcome shall be considered by analysis of variance, regression modeling, and determination of two treatment effects: Odds Ratio and Number Needed to Treat. Statistical significance for inferential statistics shall use a two-sided α with p-values fixed at ≤0.05 level of significance and 95% confidence intervals. This protocol has ethical approval from Massey University, New Zealand.
Conclusion: This novel PPS may reduce the evidence and clinical practice gap on RS delivery and ED patient outcomes, as evidenced by the emergence of COVID-19.
Keywords: COVID 19; emergency; nasal high flow; point prevalence; respiratory support.
© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9. Trials. 2020. PMID: 33115543 Free PMC article.
-
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Feb 5;22(1):116. doi: 10.1186/s13063-021-05072-4. Trials. 2021. PMID: 33546739 Free PMC article.
-
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5. Trials. 2021. PMID: 33430924 Free PMC article.
-
Nasal high flow therapy for primary respiratory support in preterm infants.Cochrane Database Syst Rev. 2023 May 5;5(5):CD006405. doi: 10.1002/14651858.CD006405.pub4. Cochrane Database Syst Rev. 2023. PMID: 37144837 Free PMC article. Review.
-
High-flow nasal oxygen therapy compared with conventional oxygen therapy in hospitalised patients with respiratory illness: a systematic review and meta-analysis.BMJ Open Respir Res. 2024 Jul 15;11(1):e002342. doi: 10.1136/bmjresp-2024-002342. BMJ Open Respir Res. 2024. PMID: 39009460 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Miscellaneous